COMP vs DRUG
COMP: Compass is a technology-enabled residential real estate brokerage that empowers real estate professionals with an integrated platform for buying, selling, and renting homes. DRUG: Bright Minds Biosciences is a clinical-stage biopharmaceutical company developing next-generation serotonin receptor agonists for CNS disorders.
Side-by-side fundamentals
| Metric | COMP | DRUG | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $9.52 | $52.00 | |
| Market cap | $7.2B | $780M | |
| P/E as of 2026-10-08 | 168.20 | n/a | |
| Net margin FY2025, SEC XBRL | -0.8% | n/a | |
| Operating margin FY2025, SEC XBRL | -0.9% | n/a | |
| ROE | -7.4% | -50.6% | COMP higher |
| ROA | -3.8% | -45.9% | COMP higher |
| Debt / equity as of 2026-09-03 | 1.12 | 0.00 | DRUG lower |
| Revenue CAGR (3y) SEC XBRL | +5.0% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.36 | 1.24 | |
| 1-year return as of 2026-10-08 close | +29.3% | -5.8% | COMP higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.